

# François Goldwasser

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5807285/publications.pdf>

Version: 2024-02-01

122  
papers

2,103  
citations

331670

21  
h-index

302126

39  
g-index

128  
all docs

128  
docs citations

128  
times ranked

3129  
citing authors

#	ARTICLE	IF	CITATIONS
1	The prevalence of CT-defined low skeletal muscle mass in patients with metastatic cancer: a cross-sectional multicenter French study (the SCAN study). <i>Supportive Care in Cancer</i> , 2022, 30, 3119-3129.	2.2	14
2	Is sarcopenia a missed factor in the management of patients with metastatic breast cancer?. <i>Breast</i> , 2022, 61, 84-90.	2.2	14
3	Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer. <i>Gynecologic Oncology</i> , 2022, , .	1.4	5
4	Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma. <i>Clinical Chemistry</i> , 2022, 68, 782-793.	3.2	7
5	Redifferentiating Effect of Larotrectinib in <i>NTRK</i> -Rearranged Advanced Radioactive-Iodine Refractory Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 594-598.	4.5	19
6	Energy expenditure profiles and the risk of early limiting toxicity in older patients with cancer: The ELCAPA-25 prospective cohort survey. <i>Clinical Nutrition</i> , 2022, 41, 1073-1082.	5.0	6
7	Preexisting Autoantibodies and Immune Related Adverse Events in Metastatic Urothelial Carcinoma Patients Treated by Pembrolizumab. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e362-e368.	1.9	7
8	Adapted physical activity in patients (Pts) with advanced pancreatic cancer (APACaP): Results from a prospective national randomized GERCOR trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4007-4007.	1.6	8
9	Creatinine-to-cystatin C ratio and bioelectrical impedance analysis for the assesment of low lean body mass in cancer patients: Comparison to L3â€œcomputed tomography scan. <i>Nutrition</i> , 2021, 81, 110895.	2.4	32
10	Quantification of nivolumab in human plasma by LC-MS/HRMS and LC-MS/MS, comparison with ELISA. <i>Talanta</i> , 2021, 224, 121889.	5.5	18
11	Simultaneous quantification of dabrafenib, hydroxy-dabrafenib and trametinib in human plasma by liquid chromatography-tandem mass spectrometry. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 193, 113718.	2.8	7
12	Re: Keiichiro Mori, Mohammad Abufaraj, Hadi Mostafaei, et al. The Predictive Value of Programmed Death Ligand 1 in Patients with Metastatic Renal Cell Carcinoma Treated with Immune-checkpoint Inhibitors: A Systematic Review and Meta-analysis. <i>Eur Urol</i> . In press. <a href="https://doi.org/10.1016/j.eururo.2020.10.006">https://doi.org/10.1016/j.eururo.2020.10.006</a> . <i>European Urology</i> , 2021, 79, e112.	1.9	2
13	Analysis of Pembrolizumab in Human Plasma by LC-MS/HRMS. Method Validation and Comparison with Elisa. <i>Biomedicines</i> , 2021, 9, 621.	3.2	6
14	Cancer during pregnancy: Factors associated with termination of pregnancy and perinatal outcomes. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 261, 110-115.	1.1	11
15	Effects of acyl-coenzyme A binding protein (ACBP)/diazepam-binding inhibitor (DBI) on body mass index. <i>Cell Death and Disease</i> , 2021, 12, 599.	6.3	13
16	Prevalence of drugâ€œdrug interactions in sarcoma patients: key role of the pharmacist integration for toxicity risk management. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 741-751.	2.3	4
17	Impact of the COVID-19 pandemic on the management of cancer patients: the experience of the cancer outpatients department of a university hospital in Paris. <i>Clinical Medicine</i> , 2021, 21, e552-e555.	1.9	1
18	Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter Study. <i>Pharmaceuticals</i> , 2021, 14, 804.	3.8	13

#	ARTICLE	IF	CITATIONS
19	Diagnostic criteria for cancer cachexia: reduced food intake and inflammation predict weight loss and survival in an international, multi-cohort analysis. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 1189-1202.	7.3	41
20	Development and validation of a host-dependent, PDL1-independent, biomarker to predict 6-month progression-free survival in metastatic non-small cell lung cancer (mNSCLC) patients treated with anti-PD1 immune checkpoint inhibitors (ICI) in the CERTIM Cohort: The ELY study. <i>EBioMedicine</i> , 2021, 73, 103630.	6.1	6
21	Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Étude des Tumeurs Uro-Génitales). <i>European Journal of Cancer</i> , 2021, 158, 1-11.	2.8	4
22	Pharmacokinetic/Pharmacodynamic Relationship of Enzalutamide and Its Active Metabolite N-Desmethyl Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 155-160.	1.9	13
23	Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients. <i>Clinical Nutrition</i> , 2020, 39, 1893-1899.	5.0	16
24	The impact of body composition parameters on severe toxicity of nivolumab. <i>European Journal of Cancer</i> , 2020, 124, 170-177.	2.8	32
25	Nivolumab increases pulmonary artery pressure in patients treated for non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 86, 497-505.	2.3	7
26	Management of Cancer Cachexia: ASCO Guideline—Time to Address the Elephant in the Room. <i>Journal of Clinical Oncology</i> , 2020, 38, 3819-3819.	1.6	1
27	Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone but decide wisely. <i>European Journal of Cancer</i> , 2020, 135, 51.	2.8	3
28	Unmet needs in clinical nutrition in oncology: a multinational analysis of real-world evidence. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989985.	3.2	42
29	Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients. <i>Clinical Therapeutics</i> , 2020, 42, 1302-1316.	2.5	13
30	Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study. <i>Cancers</i> , 2020, 12, 473.	3.7	72
31	Population Pharmacokinetics/Pharmacodynamics of Dabrafenib Plus Trametinib in Patients with BRAF-Mutated Metastatic Melanoma. <i>Cancers</i> , 2020, 12, 931.	3.7	12
32	Chapitre 23. Soins palliatifs en cancérologie. , 2020, , 613-633.		0
33	Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib. <i>Clinical Pharmacokinetics</i> , 2019, 58, 451-467.	3.5	72
34	Lack of efficacy of neoadjuvant chemotherapy in adult patients with maxillo-facial high-grade osteosarcomas: A French experience in two reference centers. <i>Oral Oncology</i> , 2019, 95, 79-86.	1.5	15
35	Body Composition in Patients with Radioactive Iodine-Refractory, Advanced Differentiated Thyroid Cancer Treated with Sorafenib or Placebo: A Retrospective Analysis of the Phase III DECISION Trial. <i>Thyroid</i> , 2019, 29, 1820-1827.	4.5	15
36	RE: Associations Between Breast Cancer Survivorship and Adverse Mental Health Outcomes: A Systematic Review. <i>Journal of the National Cancer Institute</i> , 2019, 111, 335-336.	6.3	1

#	ARTICLE	IF	CITATIONS
37	Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2019, 11, 762.	3.7	5
38	Multicentre analysis of intensity of care at the end-of-life in patients with advanced cancer, combining health administrative data with hospital records: variations in practice call for routine quality evaluation. <i>BMC Palliative Care</i> , 2019, 18, 35.	1.8	29
39	Is there an Exposure-Response Relationship for Nivolumab in Real-World NSCLC Patients?. <i>Cancers</i> , 2019, 11, 1784.	3.7	28
40	Lean Body Mass and Endocrine Status But Not Age Are Determinants of Resting Energy Expenditure in Patients with Non-Small Cell Lung Cancer. <i>Annals of Nutrition and Metabolism</i> , 2019, 75, 223-230.	1.9	4
41	Body composition and sarcopenia: The next-generation of personalized oncology and pharmacology?. , 2019, 196, 135-159.		100
42	Metabolic profile and neoadjuvant chemotherapy sensitivity in high-grade bone sarcoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e22506-e22506.	1.6	0
43	Malnutrition in Patients With Cancer: Comparison of Perceptions by Patients, Relatives, and Physicians-Results of the NutriCancer2012 Study. <i>Journal of Parenteral and Enteral Nutrition</i> , 2018, 42, 255-260.	2.6	71
44	Resting energy metabolism and anticancer treatments. <i>Current Opinion in Clinical Nutrition and Metabolic Care</i> , 2018, 21, 145-151.	2.5	11
45	Resting energy expenditure in the risk assessment of anticancer treatments. <i>Clinical Nutrition</i> , 2018, 37, 558-565.	5.0	25
46	Drug monitoring of sunitinib in patients with advanced solid tumors: a monocentric observational French study. <i>Fundamental and Clinical Pharmacology</i> , 2018, 32, 98-107.	1.9	22
47	NutriCancer: A French observational multicentre cross-sectional study of malnutrition in elderly patients with cancer. <i>Journal of Geriatric Oncology</i> , 2018, 9, 74-80.	1.0	32
48	Addition of an antiangiogenic therapy, bevacizumab, to gemcitabine plus oxaliplatin improves survival in advanced biliary tract cancers. <i>Investigational New Drugs</i> , 2018, 36, 156-162.	2.6	19
49	Low-Dose Abiraterone Regimen: Drug Monitoring Might Be the Key. <i>Journal of Clinical Oncology</i> , 2018, 36, 3061-3062.	1.6	4
50	Mental disorders associated with recent cancer diagnosis: Results from a nationally representative survey. <i>European Journal of Cancer</i> , 2018, 105, 10-18.	2.8	23
51	Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 158, 174-183.	2.8	50
52	BRCA2 Loss-of-Function and High Sensitivity to Cisplatin-Based Chemotherapy in a Patient With a Pleomorphic Soft Tissue Sarcoma: Effect of Genomic Medicine. <i>American Journal of the Medical Sciences</i> , 2018, 356, 404-407.	1.1	5
53	Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry-based study. <i>Cancer</i> , 2018, 124, 3044-3051.	4.1	17
54	A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients. <i>Pharmacological Research</i> , 2018, 136, 56-61.	7.1	11

#	ARTICLE	IF	CITATIONS
55	Sarcopenia and toxicity of the anti-PD1 inhibitors in real-life lung cancer patients: Results from the French Nationwide SCAN study.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21066-e21066.	1.6	5
56	Pharmacokinetic interaction between mitotane and etoposide in adrenal carcinoma: a pilot study. <i>Endocrine Connections</i> , 2018, 7, 1409-1414.	1.9	5
57	Specific needs of non-visceral sarcoma patients: Evidence from an early multidisciplinary intervention.. <i>Journal of Clinical Oncology</i> , 2018, 36, e22133-e22133.	1.6	0
58	Cytidine Deaminase Activity Assessment to Select Perioperative Chemotherapy Regimen in Localized Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e493-e495.	1.9	2
59	Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017, 139, 30-36.	2.8	35
60	Sarcopenic overweight is associated with early acute limiting toxicity of anti-PD1 checkpoint inhibitors in melanoma patients. <i>Investigational New Drugs</i> , 2017, 35, 436-441.	2.6	73
61	A simple HPLC-UV method for quantification of enzalutamide and its active metabolite N-desmethyl enzalutamide in patients with metastatic castration-resistant prostate cancer. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1058, 102-107.	2.3	12
62	Relation between hypermetabolism, cachexia, and survival in cancer patients: a prospective study in 390 cancer patients before initiation of anticancer therapy ., <i>American Journal of Clinical Nutrition</i> , 2017, 105, 1139-1147.	4.7	74
63	Patient-specific blood pressure correction technique for arterial stiffness: evaluation in a cohort on anti-angiogenic medication. <i>Hypertension Research</i> , 2017, 40, 752-757.	2.7	13
64	Pharmacokinetics and pharmacodynamics of tyrosine kinase inhibitors in the treatment of metastatic renal cell carcinoma. <i>International Journal of Pharmacokinetics</i> , 2017, 2, 257-283.	0.5	1
65	Erlotinib pharmacokinetics: a critical parameter influencing acute toxicity in elderly patients over 75 years-old. <i>Investigational New Drugs</i> , 2017, 35, 242-246.	2.6	20
66	Individualized Pazopanib Dosing Letter. <i>Clinical Cancer Research</i> , 2017, 23, 6377-6377.	7.0	3
67	Restoring Radioiodine Uptake in BRAF V600E Mutated Papillary Thyroid Cancer. <i>Journal of the Endocrine Society</i> , 2017, 1, 285-287.	0.2	20
68	Clinical parameters associated with anti-programmed death-1 (PD-1) inhibitors-induced tumor response in melanoma patients. <i>Investigational New Drugs</i> , 2017, 35, 842-847.	2.6	13
69	Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 2801-2811.	4.3	54
70	Renovascular Safety of Sunitinib in Renal Cell Carcinoma: The Prognostic Value of Hypertension and Proteinuria. <i>Journal of Onco-Nephrology</i> , 2017, 1, 213-219.	0.6	0
71	Antibiotics prescription to decrease progression-free survival (PFS) and overall survival (OS) in patients with advanced cancers treated with PD1/PDL1 immune checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3015-3015.	1.6	11
72	Predictive and prognostic value of systemic inflammatory response biomarkers in patients receiving nivolumab for metastatic non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3055-3055.	1.6	7

#	ARTICLE	IF	CITATIONS
73	Relationship between sarcopenia and dose-limiting toxicity (DLT) of sorafenib (SOR) in patients (pts) with advanced radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC) in the phase III DECISION trial.. Journal of Clinical Oncology, 2017, 35, e17594-e17594.	1.6	0
74	Association of muscle mass with pathologic response and toxicity in localized bladder cancer patients treated by neoadjuvant chemotherapy (NAC) and radical cystectomy (RC).. Journal of Clinical Oncology, 2017, 35, e16022-e16022.	1.6	0
75	Reply to N Dominguez and T Canada. American Journal of Clinical Nutrition, 2017, 106, 958-959.	4.7	0
76	Safety of bevacizumab in clinical practice for recurrent ovarian cancer: A retrospective cohort study. Oncology Letters, 2016, 11, 1859-1865.	1.8	8
77	Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: Clinical experience in Paris University Hospitals. European Journal of Cancer, 2016, 66, 75-82.	2.8	5
78	Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 1433-1444.	3.3	19
79	Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer. Lancet Oncology, The, 2016, 17, e468.	10.7	3
80	Angiotensin System Inhibitors in Renal Cell Carcinoma Letter. Clinical Cancer Research, 2016, 22, 524-524.	7.0	2
81	Goals and aggressiveness of care in metastatic lung cancer.. Journal of Clinical Oncology, 2016, 34, 10026-10026.	1.6	1
82	Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib. Oncotarget, 2016, 7, 67507-67520.	1.8	13
83	Everolimus and sunitinib as first- and second-line treatments of patients with metastatic papillary renal cell carcinoma (pRCC): A retrospective study of the GETUG (Groupe Français d'Etude des Tumeurs Urologiques) Tj ETQq1 1 0.784314 rgsT /Over	7.0	3
84	Aggressiveness of care at the end of life in patients with localized and advanced bladder cancer.. Journal of Clinical Oncology, 2016, 34, 10029-10029.	1.6	0
85	Integration of Oncology and Palliative Care, a Forgotten Indicator: Shared Decision Making. Oncologist, 2015, 20, e26.	3.7	9
86	Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenib Letter. Clinical Cancer Research, 2015, 21, 5639-5639.	7.0	3
87	Multicentre randomised phase II trial of gemcitabine+platinum, with or without trastuzumab, in advanced or metastatic urothelial carcinoma overexpressing Her2. European Journal of Cancer, 2015, 51, 45-54.	2.8	131
88	Sorafenib for patients with differentiated thyroid cancer. Lancet, The, 2015, 385, 227-228.	13.7	8
89	Sorafenib for patients with differentiated thyroid cancer. Lancet, The, 2015, 385, 227.	13.7	5
90	Burden of inpatient care and treatments in terminally-ill cancer patients: results from a population-based, retrospective study from administrative data in France.. Journal of Clinical Oncology, 2015, 33, 9527-9527.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Risk assessment of anticancer treatments beyond performance status: A prospective study in 277 cancer patients.. Journal of Clinical Oncology, 2015, 33, 9620-9620.	1.6	1
92	Pegylated liposomal doxorubicin-induced palmar plantar erythrodyesthesia: Identification of risks factors.. Journal of Clinical Oncology, 2015, 33, e13569-e13569.	1.6	0
93	Relationship between abiraterone plasma concentration and PSA response in metastatic castration resistant prostate cancer patients.. Journal of Clinical Oncology, 2015, 33, 5041-5041.	1.6	0
94	Is standard dose appropriate in elderly non-small cell lung carcinoma (NSCLC) patients treated with erlotinib?. Journal of Clinical Oncology, 2015, 33, 9537-9537.	1.6	0
95	Identification of candidates for sorafenib dose-escalation using sorafenib plasmatic concentration monitoring: Proof of concept.. Journal of Clinical Oncology, 2015, 33, 2572-2572.	1.6	0
96	Prevalence of malnutrition in PS 0-1 cancer patients: Results of the NutriCancer2 one-day national survey in 2,197 cancer patients.. Journal of Clinical Oncology, 2015, 33, 1587-1587.	1.6	0
97	Renovascular safety of sunitinib in prostate cancer: The prognostic value of hypertension and proteinuria.. Journal of Clinical Oncology, 2015, 33, e16056-e16056.	1.6	0
98	Feasibility of a multi-disciplinary rehabilitation program for post treatment cancer patients: A pilot study.. Journal of Clinical Oncology, 2015, 33, e20627-e20627.	1.6	0
99	Sorafenib in Thyroid Cancer Patients: Learning From Toxicity. Oncologist, 2014, 19, e3.	3.7	5
100	Phase I study of elisidepsin (Irvalec®) in combination with carboplatin or gemcitabine in patients with advanced malignancies. Investigational New Drugs, 2014, 32, 500-509.	2.6	8
101	Association of hypertension and proteinuria with overall survival in solid-tumor patients treated with anti-VEGF drugs in the MARS study.. Journal of Clinical Oncology, 2014, 32, 2548-2548.	1.6	1
102	Severe skin rash during vemurafenib treatment: A predictive factor of early positive response in metastatic melanoma?. Journal of Clinical Oncology, 2014, 32, 9092-9092.	1.6	4
103	Multidisciplinary risk assessment to reveal cancer treatments in complex cancer patients.. Journal of Clinical Oncology, 2014, 32, 170-170.	1.6	1
104	Results of the MARS study on the management of antiangiogenics™ renovascular safety in colorectal cancer.. Journal of Clinical Oncology, 2014, 32, 466-466.	1.6	0
105	Results of the MARS study on the management of antiangiogenics™ renovascular safety in renal cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 394-394.	1.6	0
106	Multidisciplinary risk assessment to reveal cancer treatments in unfit cancer patients.. Journal of Clinical Oncology, 2014, 32, 9551-9551.	1.6	0
107	Association of sunitinib exposure with toxicity outcome in a real-life population of elderly patients with cancer.. Journal of Clinical Oncology, 2014, 32, e20523-e20523.	1.6	0
108	Determinants for the decision of chemotherapy in advanced cancer patients.. Journal of Clinical Oncology, 2014, 32, 110-110.	1.6	0

#	ARTICLE	IF	CITATIONS
109	End-of-life discussions with noncurable lung cancer patients: A patients' and oncologists' qualitative study.. Journal of Clinical Oncology, 2014, 32, 151-151.	1.6	0
110	Hypertension, proteinuria, and overall survival in elderly cancer patients treated with bevacizumab.. Journal of Clinical Oncology, 2014, 32, 186-186.	1.6	0
111	Feasibility of Gemcitabine plus Oxaliplatin in Advanced Hepatocellular Carcinoma Patients with Child-Pugh B Cirrhosis. Oncology, 2013, 84, 32-38.	1.9	22
112	Results of the MARS study on the management of antiangiogenics™ renovascular safety in ovarian cancer.. Journal of Clinical Oncology, 2013, 31, 5567-5567.	1.6	5
113	Results of the MARS study on the management of antiangiogenics™ renovascular safety in breast cancer.. Journal of Clinical Oncology, 2013, 31, e12504-e12504.	1.6	1
114	How to predict sunitinib exposure and toxicity: A pharmacokinetic-pharmacodynamic study.. Journal of Clinical Oncology, 2013, 31, e15592-e15592.	1.6	1
115	Arterial stiffness to predict hypertensive response to antiangiogenic drugs.. Journal of Clinical Oncology, 2013, 31, e13589-e13589.	1.6	0
116	Effect of integrated palliative care on the quality of end-of-life care: retrospective analysis of 521 cancer patients. BMJ Supportive and Palliative Care, 2012, 2, 239-247.	1.6	38
117	Feasibility of gemcitabine and oxaliplatin in patients with advanced biliary tract carcinoma and a performance status of 2. Anti-Cancer Drugs, 2012, 23, 739-744.	1.4	18
118	First-in-human phase I and pharmacokinetic study of DTS-108 in patients with advanced carcinomas.. Journal of Clinical Oncology, 2012, 30, 2557-2557.	1.6	2
119	Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma. PLoS ONE, 2012, 7, e37563.	2.5	252
120	Management of antiangiogenics™ renovascular safety in ovarian cancer subgroup and intermediate results of the MARS study.. Journal of Clinical Oncology, 2012, 30, 5067-5067.	1.6	0
121	Management of antiangiogenics™ renovascular safety in breast cancer subgroup and intermediate results of the MARS study.. Journal of Clinical Oncology, 2012, 30, 1095-1095.	1.6	0
122	Use of platinum derivatives during pregnancy. Cancer, 2008, 113, 3069-3074.	4.1	120